期刊文献+

胃癌细胞多药耐药机制及耐药性逆转 被引量:5

Muitidrug resistance mechanisms and reversal agents in gastric carcinoma cells
原文传递
导出
摘要 中国胃癌的发病例数占全球总数的1/3。化疗是治疗胃癌的有效手段,但由于肿瘤细胞多药耐药性(MDR)的产生,化疗疗效往往不佳。深入探讨胃癌MDR产生机制,寻找有效低毒的多药耐药逆转剂,对提高化疗的有效性,延长患者的生存期有着重要的意义。从转运蛋白有关的耐药机制、酶系统有关的耐药机制、细胞凋亡与耐药、细胞因子等四方面肿瘤细胞MDR产生的机制做一简要综述。 The incidence of gastric carcinoma in our country has objected to one-third in all globe. The effective means to treat gastric carcinoma is chemical theraty, but because of production of tumor cells muhidrug resistance, ' effeetion of chemical therapy is not very good. Explore gastric carcinoma MDR mechanism, find low poison and highly efficient MDR reversal agents have more important significance for improving chemical therapeutic effectiveness, prolonging sickness survival time. Now, four mechanisms about tumor ceils multidrug resistance are summaried such as transport protein,enzyme system,programmed Cell death and cytokine.
出处 《肿瘤研究与临床》 CAS 2007年第1期68-70,72,共4页 Cancer Research and Clinic
关键词 胃肿瘤 抗药性 多药 多药耐药相关蛋白质类 反转录酶抑制剂 Gastric cancer Drug resistance, Multiple Multidrug resistance-Associated proteins Reverse transcripase inhibitors
  • 相关文献

参考文献8

二级参考文献34

  • 1赵燕秋,肖冰,陈宝军,乔泰东,樊代明.Upregulation of drug sensitivity of multidrug resistant SGC7901/VCR human gastric cancer cells by bax gene transduction[J].Chinese Medical Journal,2000(11):17-20. 被引量:10
  • 2萨姆布鲁克 EF弗里奇 等.分子克隆实验指南,第2版[M].北京:科学出版社,1992.34-57.
  • 3蔡学君,中国肿瘤临床,1992年,21卷,增刊,67页
  • 4饶本强 张胜本 见:张胜本 张连阳 主编.抗药性检测[A].见:张胜本,张连阳,主编.肿瘤化学治疗敏感性与抗药性[C].成都:四川科学技术出版社,1995.184.
  • 5Castelao JE, Bart RD 3rd, Di Perna CA, et al. Lung cancer and cyclooxygenase-2. Ann Thorac Surg, 2003, 76: 1327-1335.
  • 6Milella M, Gelibter A, DiCosimo S, et al. Pilot study of celecoxib and infusional 5-fluorouracil as second line treatment for advanced pancreatic carcinoma. Cancer, 2004, 101: 133-138.
  • 7Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol, 2003, 21: 2645-2650.
  • 8Fantappie O, Masini E, Sardi I. et al. The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. Hepatology, 2002, 35:843-852.
  • 9Schinkel AH. The physiological function of drug transporting P glycoproteins. Semin Cancer Biol, 1997, 8:161-170.
  • 10Liu Y, Hu M. P-glycoprotein and bioavailability-implication of polymorphism. Clin Chem Lab Med, 2000, 38: 877-881.

共引文献95

同被引文献40

引证文献5

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部